key: cord-0858398-2ocoh97e
authors: Planas, Delphine; Bruel, Timothée; Grzelak, Ludivine; Guivel-Benhassine, Florence; Staropoli, Isabelle; Porrot, Françoise; Planchais, Cyril; Buchrieser, Julian; Rajah, Maaran Michael; Bishop, Elodie; Albert, Mélanie; Donati, Flora; Behillil, Sylvie; Enouf, Vincent; Maquart, Marianne; Gonzalez, Maria; De Sèze, Jérôme; Péré, Hélène; Veyer, David; Sève, Aymeric; Simon-Lorière, Etienne; Fafi-Kremer, Samira; Stefic, Karl; Mouquet, Hugo; Hocqueloux, Laurent; van der Werf, Sylvie; Prazuck, Thierry; Schwartz, Olivier
title: Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
date: 2021-02-12
journal: bioRxiv
DOI: 10.1101/2021.02.12.430472
sha: be4258e643b752b5b9875e945b5a376b90f3b56c
doc_id: 858398
cord_uid: 2ocoh97e

SARS-CoV-2 B.1.1.7 and B.1.351 variants emerged respectively in United Kingdom and South Africa and spread in many countries. Here, we isolated infectious B.1.1.7 and B.1.351 strains and examined their sensitivity to anti-SARS-CoV-2 antibodies present in sera and nasal swabs, in comparison with a D614G reference virus. We established a novel rapid neutralization assay, based on reporter cells that become GFP+ after overnight infection. B.1.1.7 was neutralized by 79/83 sera from convalescent patients collected up to 9 months post symptoms, almost similar to D614G. There was a mean 6-fold reduction in titers and even loss of activity against B.1.351 in 40% of convalescent sera after 9 months. Early sera from 19 vaccinated individuals were almost as potent against B.1.1.7 but less efficacious against B.1.351, when compared to D614G. Nasal swabs from vaccine recipients were not neutralizing, except in individuals who were diagnosed COVID-19+ before vaccination. Thus, faster-spreading variants acquired a partial resistance to humoral immunity generated by natural infection or vaccination, mostly visible in individuals with low antibody levels.

pseudovirus, with slightly reduced titers in some vaccinees, when compared to the Wuhan reference strain 26, 27 . The Moderna mRNA-1273 vaccine also induces neutralizing antibodies against SARS-CoV-2 variants, with however a 5-10 fold reduction in efficacy against the B.1.351 Spike, when compared to pseudovirus bearing the D614G mutation 27, 28 .

Neutralization efficacy was so far mostly assessed using VSV-derived or lentivirus-derived pseudovirus assays, or with infectious SARS-CoV-2 carrying point mutations in the Spike. One recent report using infectious B.1.351 virus showed that plasma from six convalescent donors were strongly attenuated against this strain, with 6 to 200-fold higher IC50 values relative to ancestral virus 29 . It is thus of outmost importance to use authentic variant strains in addition to pseudovirus particles to evaluate their sensitivity to antibodies. Here, we compared the sensitivity of three authentic SARS-CoV-2 strains, the pre-existing D614G virus and the B.1.1.7 and B.1.351 variants, to antibody neutralization.

We isolated the two variants from nasal swabs of patients with RT-qPCR and sequence-diagnosed infection. The viruses were amplified by one to two passages on Vero cells. Sequences of the outgrown viruses confirmed the identity of B.1.1.7 and B.1.351 variants. Viral stocks were titrated using S-Fuse reporter cells 30 . These cells are derived from U2OS-ACE2+ cells and carry the GFP-split system. Upon infection, the cells produce the Spike at their surface and fuse with neighbouring cells, generating a GFP signal after a few hours 30 (Fig. 1a) . The number of GFP+ cells correlated with the viral inoculum ( Fig. 1b) . Neutralizing anti-SARS-CoV-2 monoclonal antibodies (mAb) targeting the RBD can be classified into 4 main categories 31, 32 . We tested with the S-Fuse assay the sensitivity of the three viral strains to two anti-RBD antibodies, mAb102 and mAb48, that belong to the first category, and act by blocking ACE2 and binding to "up" RBDs 32 . MAb102 efficiently and similarly neutralized the three viral strains, with IC50 of ≃ 0.01 µg/mL (Fig. 1c,d) . MAb48 neutralized D614G (IC50 of 0.1 µg/mL) but was inactive against B.1.1.7 and B.1.351 variants (Fig. 1c,d) . These results confirmed that the two variants selectively display reduced sensitivity to certain antibodies. Of note, the activity of the mAbs was similar at different viral inocula, within a range of 50 to 200 GFP+ syncytia/well (Fig. 1e) , indicating that potential variations in the number of infected S-Fuse cells do not impact the calculation of IC50. We thus selected for further studies a multiplicity of infection leading to about 150 syncytia/well for each viral strain.

We then assessed the neutralization ability of sera from convalescent individuals. We randomly selected 28 samples in a longitudinal cohort of infected individuals from the French city of Orléans (Table S1 ). They were all diagnosed for COVID-19 by RT-qPCR or serology and included critical, severe, and mild-to-moderate cases. 25 individuals were sampled twice, firstly at a median of 89 days (range: 77-105) post onset of symptoms (POS) (Month 3 samples (M3)), and secondly at a median of 179 days (range 168-197) POS (M6 samples). We incubated serially diluted sera with D614G, B.1.1.7 or B.1.351 strains, added the mixture to S-Fuse cells, and scored the GFP+ cells after overnight infection. We then calculated ED50 (Effective Dose 50%) for each combination of serum and virus. A representative example with the same donor is depicted Fig. 2a , and the results with all donors appear in Fig. 2b . The D614G and B.1.1.7 strains were similarly sensitive to sera. At M3, the median ED50 values were respectively 1.5x10 3 and 1x10 3 for D614G and B.1.1.7 variants, with huge variations between individuals (from 10 2 to 2x10 4 ) and the values did not strongly decline at M6. As expected, individuals with critical conditions displayed higher neutralizing activities than those with severe or mild-tomoderate symptoms (Fig. S1 ). Again, there was no significant difference between the two viral strains in each category of symptoms. With B1.351, the neutralization titers were significantly decreased by 5 and 10-fold at the two time-points, when compared with D614G and B.1.1.7 strains ( Fig. 2b and S1).

We confirmed these results in 30 sera from another cohort of RT-qPCR-confirmed staff from Strasbourg University Hospitals that experienced a mild disease 33, 34 . The samples were collected at a later time point (M9), with a median of 233 days (range 206-258) POS (Table S1 ). Overall, the neutralization activity was lower (one representative example is shown in Fig. 2a and the results of all donors in Fig. 2b ). There was no significant difference in neutralization between D614G and B.1.1.7 strains, with a similar ED50 of 2x10 2 . In sharp contrast, the neutralizing activity against B.1.351 was particularly low at this late time point, with a median ED50 of 50, representing a 4-fold decrease when compared to D614G (Fig. 2b) .

We then arbitrarily classified the cases as neutralizers (with neutralizing antibodies detectable at the first serum dilution of 1/30) and non-neutralizers, for the three viral strains and the two cohorts ( Fig.   2c ). Most of individuals neutralized the three strains at M1. The fraction of neutralizers started to decline at M6, a phenomenon which was more marked with B. Similar surface levels of the viral proteins were detected with mAb10, a non-neutralizing pan-coronavirus antibody targeting a conserved epitope in the S2 domain (Fig. 3a,b and Fig. S2 ). Moreover, the cells fused when co-cultivated with ACE2-expressing cells, indicating that the three proteins were functional (not shown). The mAb102 similarly bound to the three Spikes, in accordance with its crossreactive neutralizing activity. mAb48 efficiently bound to D614G Spikes, slightly less potently to B.1.1.7, and lost any binding activity to B.1.351. Therefore, the escape of mAb48 neutralization by the two variants is due to mutations decreasing or abrogating antibody binding to its target. The N501Y mutation enhances RBD affinity to ACE2, when tested with recombinant proteins and yeast surface display 20 . We assessed by flow cytometry the binding of a labelled soluble ACE2 protein to cells expressing the different Spikes. We observed a dramatic increase of binding of soluble ACE2 to B.1.1.7

and to a lesser extent to B.1.351, which both carry the N501Y mutation, when compared to D614G ( Fig. 3a,b) .

We next tested our panel of 83 sera from convalescent individuals against the different Spikes. Overall, the sera similarly bound to the Spikes, even though B.1.351 displayed a slight reduction in the mean fluorescence intensity (MFI) of binding (Fig. 3c ). We observed a global and slight decrease of MFI at M9, compared to samples from M3 and M6 (Fig. 3d) . Altogether, these results indicate that Spikes from B.1.351 and to an higher extent B.1.1.7 display increased affinity for ACE2, while escaping binding to some monoclonal antibodies and either to a lesser degree or not at all to polyclonal sera. Table S2 . Sera and nasal swabs were sampled at week 2 (17 individuals) and

week 3 (18 individuals), week 4 (11 individuals, corresponding to week 1 after the second dose), with a median of 13, 19 and 28 days after the first dose, respectively. This allowed us to assess the early humoral response to vaccination. We first analyzed the 16 out of 19 vaccinees that have not been previously infected with SARS-CoV-2, as assessed by the absence of pre-existing anti-S antibodies and anti-N antibodies. A representative example of the evolution of the neutralizing response in one vaccine recipient at the three time-points is depicted Fig. 4a . In this case, the serum only neutralized D614G at week 2, whereas B.1.1.7 started to be neutralized at week 3, although less efficiently than D614G. B.1.1.7 and D614G strains were similarly neutralized at week 4. The anti-B.1.351 response was negative up to week 3, and became detectable at week 4, at a level lower than the two other viruses.

The ED50 results with the 16 vaccine recipients are presented Fig. 4b . We also arbitrarily classified the cases as neutralizers (with neutralizing antibodies detectable at the first serum dilution of 1/30) and non-neutralizers, for the three viral strains (Fig. 4c) . Two weeks after vaccination, antibodies neutralizing the D614G strain were detected in the sera of 5/15 recipients (33%, with an arbitrary threshold of ED50> 30 for neutralization positivity ) (Fig. 4b,c) . The titers were relatively modest at this early time point (median ED50: 30). These low titers were less efficient against B.1.1.7, with 2/15 neutralizers (13%), and inactive against B.1.351 (Fig. 4b,c ). At week 3, the neutralizing activity increased against D614G and B.1.1.7. There was however a 3-fold reduction in the neutralization titers with B.1.1.7 (Fig. 4b) in the sera correspond to a protection against severe disease.

Little is known about the levels and function of vaccine-elicited antibodies in mucosal samples. We thus measured the neutralizing activity of nasal swabs from the series of vaccine recipients (Fig. 5) . We did not detect any antiviral effect in these samples at two and three weeks post vaccination (Fig. 5a ,b)

We also analyzed three additional vaccine recipients who were seropositive for N at the time of vaccination, indicative of a previous infection. Two were diagnosed SARS-CoV-2 positive by PCR in March and April 2020 and experienced a mild disease. The third did not report any previous signs reminiscent of COVID-19. In these three individuals, the neutralizing titers were strikingly high at week 2 in their sera (ED50 of about 10 4 ) (Fig. 5c ). Two out of the three vaccine recipients who were previously seropositive for SARS-CoV-2 displayed a neutralizing activity in their nasal swabs (Fig. 5d ,e). Their nasal swabs similarly neutralized the D614G and B.1.117 strains and were inactive against B.1.351. The levels of anti-Spike antibodies and their neutralization activity in the sera and nasal swabs of vaccine recipients are summarized in the heat map presented in Fig. 5f . In the swabs, we detected anti-SARS-CoV-2 antibodies in 6/17 available samples at week 2, 7/13 at week 3, 8/10 at week 4 ( Fig. 5f ). The three COVID-19+ vaccine recipients were those with highest antibody levels in the nasal swab.

Unfortunately, we did not have access to their nasal swabs before vaccination, precluding determining whether previous infection, vaccination, or more likely the combination of both generated a neutralizing response in these individuals. Altogether, our results strongly suggest that vaccinees do not generally elicit an early humoral response detectable at mucosal surfaces. They strengthen the hypothesis that some vaccines may not protect against viral acquisition and infection of the oral-nasal region but may prevent severe disease associated with viral dissemination in the lower respiratory track.

Here, we analyzed the cross reactivity of the humoral response to pre-existing SARS-CoV-2 viruses and recently emerging variants, in sera from long-term convalescent individuals and recent vaccine recipients. We report that immune sera had slightly reduced but largely preserved activity against B.1.1.7 when compared to the reference D614G strain. The B.1.351 variant is more problematic as it is less sensitive or even unsensitive to a large part of the sera tested, particularly when global antibody levels are low. The E484K mutation, responsible for antibody escape of B.1.351 and P.1 variants, has been recently detected in the B.1.1.7 lineage in UK, and thus represents a major threat for previously immune populations. Here, we used authentic clinical viral isolates, rather than pseudovirus, providing a relevant way to assess inherent viral fitness and potential impact of additional mutations outside of Spike on sensitivity to neutralizing antibodies. On a technical note, the combination of S-Fuse and S-Flow assays, two methods of analysis of viral infectivity, neutralization or antibody levels, allowed a rapid assessment of the properties of emerging variants. The workflow established here can be easily adapted to any novel viral strain. Potential limitations of our study are the relatively low number of individuals analyzed and the short time frame of analysis after vaccination. Furthermore, we have not investigated the impact of pre-existing cellular immunity, which may be more cross-reactive against variants than the humoral response. Future work with more vaccine recipients that have or haven't been previously infected, and longer periods of survey, will help characterizing the role of local and systemic humoral responses in vaccine efficacy. In conclusion, our results demonstrate that suboptimal or declining antibody responses are associated with a loss of cross-reactivity against novel emerging viral strains.

No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Qualitative results as well as index values were used for analysis for both assays.

S-Flow Assay. The S-Flow assay was performed as described 33, 35 . Briefly, HEK293T (referred as 293T) cells were acquired from ATCC (ATCC ® CRL-3216™) and tested negative for mycoplasma. 293T Cells were transfected with the indicated Spike expression plasmids or a control plasmid using Examples of neutralization curves with sera from two donors. The first donor, from the Orléans Cohort, was sequentially sampled at month 3 (M3) and M6 (left and middle panels, respectively). The second donor, from the Strasbourg Cohort, was sampled at M9 (right panel). Results are shown as mean ± SD from two to four independent experiments. b. ED50 of neutralization of the three viral isolates. 28 sera from the Orléans Cohort were sequentially sampled at month 3 (M3) and M6 (left and middle panels, respectively), and 30 sera from the Strasbourg Cohort were sampled at M9 (right panel). Data are mean from two to four independent experiments. Friedman test with Dunn's multiple comparison was performed between each viral strain at the different time points, *: p-value<0.05 **: p-value<0.01 **** p<0.001. c. Each subject was arbitrarily defined as "neutralizer" (in blue) if a neutralizing activity was detected at the first (1/30) serum dilution or "non-neutralizer" (in grey) if no activity was detected. The numbers indicate the % of neutralizers. 

Structural and Functional Analysis of the D614G SARS-CoV-2

Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ΔH69/V70. Biorxiv

Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion. medRxiv

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Spike mutation D614G alters SARS-CoV-2 fitness

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

SARS-CoV-2 escape <em>in vitro</em> from a highly neutralizing COVID-19 convalescent plasma

The impact of Spike mutations on SARS-CoV-2 neutralization

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with

Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

SARS-CoV-2 RBD <em>in vitro</em> evolution follows contagious mutation spread, yet generates an able infection inhibitor

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccineelicited sera

Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes. medRxiv

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. medRxiv

Syncytia formation by SARS-CoV-2 infected cells

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France

Sex differences in the decline of neutralizing antibodies to SARS-CoV-2. medRxiv

A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficient generation of human IgA monoclonal antibodies

We thank Felix Rey & Lisa Chakrabarti for critical reading of the manuscript. We thank patients who participated to this study, members of the Virus and Immunity Unit for discussions and help, Nathalie Aulner and the UtechS Photonic BioImaging (UPBI) core facility (Institut Pasteur), a member of the France BioImaging network, for image acquisition and analysis, Marija Backovic for the ACE2 construct.We thank the DRCI, CIC, Médecine du travail and Pôle de Biologie teams (CHU de Strasbourg) for the management of the Strasbourg cohort and serology testing.